INNOVATE: Identifying Novel Aging Targets for Treatment of Delirium

Sponsor
Wake Forest University Health Sciences (Other)
Overall Status
Terminated
CT.gov ID
NCT03682874
Collaborator
(none)
5
1
16.4
0.3

Study Details

Study Description

Brief Summary

The long-term goal of this research program is to improve understanding of the mechanistic link between Alzheimer's disease (AD) neuropathology, acute delirium, and cognitive impairment following acute respiratory failure. In this pilot study, the study team will establish a prospective cohort of older patients with acute respiratory failure and obtain data on delirium duration, AD imaging and CSF biomarkers, and cognitive outcomes following critical illness.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The study team will recruit patients with no known history of dementia for enrollment into the cohort during their hospital stay for acute respiratory failure. The cohort will undergo testing including cognitive testing, MRI imaging, lumbar puncture for cerebrospinal fluid (CSF) analysis at 3 months following hospital discharge. The study will examine the association of delirium duration during the hospital stay and cognitive impairment at 3 month follow-up with CSF levels of amyloid- β42, tau, and phospho-tau. Measures of delirium will also be related with structural/functional MRI dependent measures. The goal is to design a larger prospective cohort study to evaluate the relationship between AD imaging and CSF biomarkers with delirium and post-ICU cognitive impairment. The results of this pilot study with provide important information with regard to future study design including: (1) ratio of eligible to recruited patients (2) retention rate; (3) safety and feasibility of protocol; and (4) preliminary effect size estimates.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    5 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Identifying Novel Aging Targets for Treatment of Delirium
    Actual Study Start Date :
    Oct 10, 2018
    Actual Primary Completion Date :
    Feb 20, 2020
    Actual Study Completion Date :
    Feb 20, 2020

    Outcome Measures

    Primary Outcome Measures

    1. Structural/functional MRI dependent measures [2-5 months after hospital discharge]

      gray matter volume

    2. Structural/functional MRI dependent measures [2-5 months after hospital discharge]

      cerebral blood flow

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    55 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age greater than or equal to 55 years

    • Anticipated ICU stay of at least 48 hours

    • Delirium during ICU stay defined as CAM-ICU positive on at least two occasions at least 12 hours apart within 72 hours.

    Exclusion Criteria:
    • Diagnosis of dementia in electronic medical record at time of ICU admission

    • Blindness, deafness, or inability to understand English as this prevents ICU delirium assessment

    • Cognitive impairment prior to hospitalization (inability to follow instructions/comply with study/sign consent)

    • Score of > 3.30 on Informant Questionnaire of Cognitive -Decline in the Elderly (IQCODE)[34]. Questionnaire will be given to family member or legally authorized representative.

    • Pregnancy/lactating/breastfeeding

    • Legally incapacitated: Prisoner/Ward of State

    • History of prior large vessel cerebrovascular accident (CVA)

    • History of neurologic disorder prior to ICU admission including multiple sclerosis, Parkinson disease, epilepsy, amyotrophic lateral sclerosis (ALS), Guillain-Barre Syndrome (GBS)

    • Psychiatric illness including schizophrenia, bipolar disorder, depression with psychotic features

    • Not expected to survive 24 hours

    • Judgment of investigator that subject participation could jeopardize subject health/safety or integrity of study

    • Active malignancy requiring treatment in the prior 6 months

    • Inability to return for study procedures

    • Inability to obtain consent

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Wake Forest Baptist Health Winston-Salem North Carolina United States 27157

    Sponsors and Collaborators

    • Wake Forest University Health Sciences

    Investigators

    • Principal Investigator: Jessica A Palakshappa, MD, Wake Forest

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Wake Forest University Health Sciences
    ClinicalTrials.gov Identifier:
    NCT03682874
    Other Study ID Numbers:
    • IRB00052417
    First Posted:
    Sep 25, 2018
    Last Update Posted:
    Jun 30, 2021
    Last Verified:
    Mar 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 30, 2021